This prediction is mechanistically comparable with our previously reported loss of ORMDL-mediated inhibition of SPT in SPTLC1-associated ALS variants that cluster in the first transmembrane domain of SPTLC1, where it interacts with ORMDL3.5 10. Here, ORMDL3 is linked to amyotrophic lateral sclerosis.